Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC

INTRODUCTION: The introduction of consolidation immunotherapy after chemoradiotherapy has improved outcome for patients with locally advanced non-small cell lung cancer. However, not all patients receive this treatment. This study identifies factors associated with failure to start durvalumab as con...

Descripción completa

Detalles Bibliográficos
Autores principales: Langberg, Christian Wilhelm, Horndalsveen, Henrik, Helland, Åslaug, Haakensen, Vilde Drageset
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354813/
https://www.ncbi.nlm.nih.gov/pubmed/37476372
http://dx.doi.org/10.3389/fonc.2023.1217424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354813/
https://www.ncbi.nlm.nih.gov/pubmed/37476372
http://dx.doi.org/10.3389/fonc.2023.1217424

Ejemplares similares